Table 1.
Sociodemographic and clinical characteristics of primary care patients with chronic kidney disease and type 2 diabetes mellitus in Muscat, Oman (n=300)
| Characteristic | N (%) |
|---|---|
| Gender | |
| Male | 156 (52.0) |
| Female | 144 (48.0) |
| Age (years) | |
| 20–35 | 15 (5.0) |
| 36–50 | 122 (40.7) |
| 51–65 | 163 (54.3) |
| BMI (kg/m2) | |
| <18.5 | 1 (0.3) |
| 18.5–24.9 | 35 (11.7) |
| 25–29.9 | 115 (38.3) |
| ≥30 | 149 (49.7) |
| Duration of T2DM (years) | |
| <3 | 47 (15.7) |
| 3–5 | 45 (15.0) |
| 5–10 | 117 (39.0) |
| >10 | 91 (30.3) |
| Stage of CKD | |
| Stage 1 | 188 (62.7) |
| Stage 2 | 103 (34.3) |
| Stage 3 | 9 (3.0) |
| Stage 4 | 0 |
| Stage 5 | 0 |
| ACR | |
| Normal | 200 (66.7) |
| Abnormal | 83 (27.7) |
| Hypertension | |
| Yes | 140 (46.7) |
| No | 160 (53.3) |
| Dyslipidemia | |
| Yes | 201 (67.0) |
| No | 99 (33.0) |
| Taking ACEIs | |
| Yes | 119 (39.7) |
| No | 181 (60.3) |
BMI=Body mass index, T2DM=Type 2 diabetes mellitus, CKD=Chronic kidney disease, ACR=Albumin-to-creatinine ratio, ACEIs=Angiotensin-converting enzyme inhibitors